Kazia Therapeutics Files 6-K with SEC
Ticker: KZIA · Form: 6-K · Filed: Sep 23, 2024 · CIK: 1075880
Sentiment: neutral
Topics: sec-filing, compliance, foreign-issuer
TL;DR
Kazia Therapeutics (KZA) filed a 6-K, standard SEC report for foreign issuers.
AI Summary
Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on September 23, 2024. The company, headquartered in Sydney, NSW, is a foreign private issuer and is submitting this report under the Securities Exchange Act of 1934. Kazia Therapeutics is involved in the pharmaceutical preparations industry.
Why It Matters
This filing indicates ongoing regulatory compliance and reporting for Kazia Therapeutics as a foreign private issuer, which is standard for companies with international operations listed on US exchanges.
Risk Assessment
Risk Level: low — A Form 6-K is a routine filing for foreign private issuers and does not typically contain material non-public information that would significantly alter risk.
Key Players & Entities
- Kazia Therapeutics Limited (company) — Registrant
- Novogen Ltd (company) — Former company name
- 000-29962 (dollar_amount) — SEC File Number
- 20240923 (date) — Filing Date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934. It is used to provide information that the company has made or is required to make public in its home country, has filed or is required to file with a stock exchange, or has distributed or is required to distribute to its security holders.
When was Kazia Therapeutics Limited previously known as?
Kazia Therapeutics Limited was formerly known as Novogen Ltd, with a date of name change recorded as December 28, 1998.
What is Kazia Therapeutics Limited's primary business classification?
Kazia Therapeutics Limited is classified under Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
Where is Kazia Therapeutics Limited's principal executive office located?
The principal executive office of Kazia Therapeutics Limited is located at Three International Towers, Level 24, 300 Barangaroo Avenue, Sydney NSW 2000.
Does Kazia Therapeutics Limited file annual reports under Form 20-F?
Yes, Kazia Therapeutics Limited indicates it files annual reports under cover of Form 20-F.
Filing Stats: 291 words · 1 min read · ~1 pages · Grade level 13.5 · Accepted 2024-09-23 09:23:50
Filing Documents
- d836917d6k.htm (6-K) — 10KB
- d836917dex991.htm (EX-99.1) — 12KB
- g836917g0920231400068.jpg (GRAPHIC) — 4KB
- 0001193125-24-223336.txt ( ) — 29KB
From the Filing
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrants name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): INFORMATION CONTAINED IN THIS FORM 6-K REPORT On September 23, 2024, Kazia Therapeutics Limited (the Company) issued a press release titled, Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium. A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the quote of Dr. John Friend, Chief Executive Officer of the Company, contained in Exhibit 99.1, into the Companys registration statements on Form F-3 (File No. 333-276091 and 333-281937). EXHIBIT LIST Exhibit Description 99.1 Press Release of Kazia Therapeutics Limited dated September 23, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Kazia Therapeutics Limited (Registrant) /s/ John Friend John Friend Chief Executive Officer Date: 23 September 2024